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Abstract: New generation oxygenators with integrated
arterial line filters have been marketed to improve the
efficacy of cardiopulmonary bypass (CPB). Differences in
designs, materials, coating surfaces, pore size of arterial
filter, and static prime exist between the oxygenators.
Despite abundant preclinical data, literature lacks clinical
studies. From September 2010 to March 2011, 80 consecu-
tive patients were randomized to CPB using Terumo
Capiox FX25 (40 patients, Group-T) or Sorin Synthesis (40
patients, Group-S) oxygenators. Pressure drop and gas
exchange efficacy were registered during CPB. High-
sensitivity C-reactive protein (hs-CRP), white blood cells
(WBCs), fluid balance, activated clotting time, interna-
tional normalized ratio (INR), activated partial thrombo-
plastin time (aPTT), fibrinogen, platelets (PLTs), serum
albumin, and total proteins were measured peri-
operatively at different timepoints. Clinical outcome was
recorded. Repeated measure analysis of variance and non-
parametric statistics assessed between-groups and during
time differences. The two groups showed similar baseline
and intraoperative variables. No differences were recorded
in pressure drop and gas exchange (group-P and
group*time-P = N.S. for all) during CPB. Despite similar
fluid balance (P = N.S. for static/dynamic priming
and DVolume administered intraoperatively), Group-T
showed higher hs-CRP (group-P = 0.034), aPTT (group-
P = 0.0001), and INR (group-P = 0.05), with lower serum
albumin (group-P = 0.014), total proteins (group-P =
0.0001), fibrinogen (group-P = 0.041), and PLTs (group-
P = 0.021). Group-T also showed higher postoperative
bleeding (group-P = 0.009) and need for transfusions
(P = 0.008 for packed red cells and P = 0.0001 for fresh
frozen plasma and total transfused volumes). However,
clinical outcome was comparable (P = N.S. for all clini-
cal endpoints). Both oxygenators proved effective and
resulted in comparable clinical outcomes. However, Sorin
Synthesis seems to reduce inflammation and better pre-
serve the coagulative cascade and serum proteins, resulting
in lower transfusions and post-CPB inflammatory res-
ponse. Key Words: Cardiopulmonary bypass—Oxyge-
nators—Integrated arterial filters—Arterial filter.
Since the beginning of cardiac surgery, it was rec-
ognized that cardiopulmonary bypass (CPB) induces
a systemic inflammatory reaction that results in
increased postoperative morbidity and hospital
stay (1,2). Accordingly, several studies have focused
on the systemic inflammatory response syndrome
(SIRS), and progressive technical refinements to the
CPBmachine have been suggested to attenuate SIRS
(1,2). It has been suggested that coated circuits
improve postoperative outcome compared with the
traditional uncoated ones (2). It has been reported
that different types of coating attenuate inflamma-
tory response (2), platelet (PLT) activation (3), fibrin-
olysis (4), need for transfusions (5), postoperative
cerebral dysfunction (6), and myocardial damage (7)
compared with the “uncoated” technology. Thus, the
overall concordance of the literature on this topic has
led to the general recommendation to use coated
circuits in the daily surgical practice (2). Similarly,
published guidelines have concluded that “heparin-
coated bypass circuits (oxygenator alone or the entire
circuit) are not unreasonable for blood conservation”
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(Class IIb-Level of Evidence B) (8) and that “reduc-
tion of circuit surface and the use of biocompatible
surface-modified circuits might be useful—effective
in reducing the systemic inflammatory response”
(Class IIa- Level of Evidence B) (1).
Similarly, gaseous microemboli (GME), generated
during CPB by perfusionist interventions, surgical
manipulations, temperature changes as well as by the
CPB circuit components, have been promptly recog-
nized as important contributing factors to embolic
organ damage and, consequently, as specific triggers
of SIRS (9). Accordingly, arterial line filters have
been proposed (and afterward proved) to signifi-
cantly reduce the load of gaseous and particulate
emboli (10). A systematic review of the data related
to the arterial line filtration strategy has reported that
the level of evidence supporting this practice was as
high as Class I-Level of Evidence A (1). Finally, min-
iaturization of the CPB machine has proved to be
effective in reducing pump-priming, inflammation,
blood loss, and donor blood usage (11–13).
Innovative CPB settings have been developed in
order to integrate the above-mentioned concepts of
“surface-coating,” “blood-filtration,” and “miniaturi-
zation.” Indeed, the integration of arterial line filters
with oxygenators fulfill these principles. However,
although these innovations have been often com-
pared with traditional CPB equipment, no study—to
the best of our knowledge—has ever evaluated the
clinical impact of the dissimilar “coating” and “filter-
ing properties” offered by the available oxygenators
with integrated arterial line filters. Therefore, it was
the aim of this study to investigate the clinical and
biochemical outcome related to the use of two differ-
ent “coated” oxygenators with integrated arterial
filter in routine surgical practice.
PATIENTS AND METHODS
Patients and technical equipments
From September 2010 to March 2011, 80 consecu-
tive adult patients undergoing isolated primary aortic
valve replacement (AVR) under CPB were prospec-
tively randomized to undergo extracorporeal circula-
tion using the Terumo Capiox FX25 oxygenator (40
patients,Group-T [Terumo Italia Srl,Rome, Italy]) or
the Sorin Synthesis oxygenator (40 patients, Group-S
[Sorin Group Italia, Mirandola, Modena, Italy]).
Briefly, the Terumo Capiox FX25 woven hollow-fiber
oxygenator sustains up to 7 L/min of blood flow,
requires a static prime of 250 mL, has a surface area
of 2.5 m2, a biocompatible coating with poly-2-
methoxyethylacrylate (so-called X-coating), and an
integrated polyester arterial line filter of 32 mm pore
size. However, the Sorin Synthesis oxygenator has a
microporous polypropylene membrane requiring a
static prime of 430 mL with a surface of 2.0 m2, sus-
tains up to 8 L/min of blood flow, and has a biocom-
patible phosphorylcholine coating with an integrated
polyester arterial line filter of 40 mm pore size. Com-
plete technical properties of both oxygenators are
available online at http://www.terumo-cvs.com/doc/
819820_FXFamilyBrochure_2009.pdf and http://
www.sorin.com/sites/default/files/product /files/2010/
10/07/09330-37_Synthesis.pdf, respectively (accessed
October 27, 2011).
The study protocol was approved by the Institu-
tion’s Ethical Committee/Institutional Review
Board. Informed consent was obtained from each
patient. Due to the investigation of both the clinical
and the biochemical response to two different oxy-
genators, strict enrollment criteria and standardized
protocols were defined.
Inclusion/exclusion criteria
Only patients scheduled for low-risk primary elec-
tive isolated AVR because of calcified degenerative
aortic valve stenosis were enrolled in the study. In
order to avoid potential bias related to prolonged
CPB, this choice was dictated by the low-risk and
rapid nature of these procedures (14).
All factors potentially interfering with the myocar-
dial and/or the systemic inflammatory responses
were considered exclusion criteria. In particular, in
order to avoid the risk of bias related to an uneven
distribution of cardioplegic solutions, patients with
coronary disease were excluded from the study.
Other exclusion criteria were: age <18 or >85 years,
emergent/urgent/salvage procedures, left ventricular
ejection fraction <35% at preoperative echocardio-
graphy, associated cardiac or vascular surgical
procedures, redo surgery, recent (<8 weeks) acute
myocardial infarction, preoperative intra-aortic
balloon pump assistance, severe chronic obstructive
pulmonary disease (Stage IIIa of Global Initiative
for Chronic Obstructive Lung Disease [GOLD] clas-
sification), obesity (body mass index >30 kg/m2),
renal disease (Kidney Disease Outcome Quality Ini-
tiative class 2), previous irradiation, previous tho-
racic surgery, previous transfusions (within 6
months), recent (<30 days) infections, liver dysfunc-
tion, ongoing steroids or statins, drug abuse,
neurologic diseases or recent (<3 months) stroke,
acquired/congenital deficits of the immune system,
autoimmune diseases, and cancer. On the day of
surgery, patients were randomized by lottery, drawing
preprepared sealed envelopes containing the group
assignment. With the exception of the main investi-
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gator and of the CPB technician, all other physicians
(surgeons, anesthesiologists, intensivists, biochemists,
etc.) dealing with perioperative patient care, biologi-
cal sampling, and/or collection and analysis of clinical
data were blinded to the group assignment until the
end of the study.
Anesthesia and surgery
Anesthesia was standardized. No steroids were
administered throughout the procedure. Anesthetic
induction consisted of intravenous propofol infusion
at 2 mg/kg combined with fentanyl administration at
0.010 mg/kg. Propofol infusion (150–200 mg/kg/min)
and isoflurane (0.8% inspired concentration) main-
tained anesthesia in the operating room. Neu-
romuscular blockade was achieved by 4 mg/h of
vecuronium bromide, and lungs were ventilated to
normocapnia with a volume-controlled ventilation, at
a frequency of 12/min, a tidal volume of 8 mL/kg of
ideal body weight, and an administered oxygen frac-
tion (FiO2) of 0.5.A positive end-expiratory pressure
(PEEP) was set at 5 cm/H2O. During CPB, mechani-
cal ventilation was discontinued.Arterial and central
venous catheters were the standard.During intensive
care unit (ICU) stay, lungs were ventilated mechani-
cally for at least 4 h after termination of surgery, with
volume-controlled ventilation, at an initial frequency
of 12/min, a tidal volume of 8 mL/kg of ideal body
weight, and a PEEP maintained at 5 cm/H2O during
the entire study period. FiO2 and ventilation rates
were then adjusted to keep arterial partial oxygen
pressure (PaO2) >120 mm Hg and arterial partial
carbon dioxide pressure (PaCO2) between 30 and
35 mm Hg. Airway clearance was maintained by
means of closed routine tracheal suctioning.Anesthe-
sia was maintained with continuous propofol infu-
sion (180–200 mg/kg/min), plus intravenous fentanyl
administration if requested, until the start of the
weaning from mechanical ventilation. Mechanical
ventilation (FiO2 and ventilation rate) was adjusted
during ICU stay to keep acid–base balance and
PaCO2 between 40 and 45 mm Hg. Analgesia was
guaranteed by routine opioid administration.
Surgery was always performed through a median
sternotomy. Bioprosthetic or mechanical AVRs were
accomplished according to conventional guidelines.
In all cases, supra-annular prosthetic anchorage was
achieved by interrupted pledgeted noneverting
sutures.
CPB was accomplished always by the same two
senior perfusionists, through strict adherence to the
established standardized protocol.Heparin was given
at a dose of 300 IU/kg to achieve a target activated
clotting time of 480 s or above. Left ventricular
venting through the right superior pulmonary vein
and cardiotomy suction, until protamine administra-
tion, were routinely employed. Returned blood was
always reinfused to the patient. Blood recovery with
an autotransfusion device (Autotrans Dideco,Miran-
dola, Modena, Italy) was also performed intraopera-
tively in all cases. A level of hemoglobin lower than
8 g/dL prompted blood transfusion. The extracorpo-
real circuit was primed with NaCl 0.9% solution and
5000 IU of heparin. A nonpulsatile CPB flow was
established at 2.4 L/min/m2.All patients were cooled
to moderate hypothermia, ranging from 32 to 34°C.
Cardiac arrest and myocardial protection were
accomplished by means of aortic cross-clamping
coupled with intermittent antegrade and retrograde
hyperkalemic cold blood cardioplegia (1:4 ratio),
followed by a retrograde “hot shot” immediately
before aortic declamping, as already reported (15).
Repeated doses were administered every 20 min.
Composition of the crystalloid solutions mixed
with blood in a 1:4 ratio for antegrade bolus, retro-
grade maintenance, and predeclamping “hot shot”
are reported in Table 1. CPB circuit was similarly
standardized. It included a Terumo X-coated tubing
set (Terumo Italia Srl) or Sorin phosphorylcholine-
coated tubing set (Sorin Group SpA, Milano, Italy)
for patients randomized to Group-T and Group-S,
respectively, and a Jostra roller pump (Jostra,Maquet
Cardiopulmonary, Hirrlingen, Germany). Blood gas
management during CPB aimed at a pH between
7.35 and 7.40 and PaCO2 between 35 and 40 mm Hg.
PaO2 was maintained higher than 200 mm Hg.Alpha-
stat was chosen for blood gas management.
Following surgery, patients received anticoagula-
tion with enoxaparin, starting when the postoperative
bleeding was controlled (usually within 6 h), until the
TABLE 1. Composition of each unit of crystalloid solution used for myocardial protection
Glucose
50% (mL) CPD (mL)
NaCl
30% (mL)
NaCl
0.9% (mL)
Trometamol
(mL)
KCl
3 mEq/mL
(mL) Energy (kJ) Osmolarity
Bolus 55 50 6.5 500 200 20 481 748
Maintenance 55 50 6.5 500 200 7 481 651
Hot shot 225 225 250 40 225 9 611 701
CPD, citrate-phosphate-dextrose.
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third postoperative day, associated to a daily dose of
100 mg acetylsalicylic acid. Oral anticoagulation with
warfarin was started on the first postoperative day
with a target INR of 2.5–3.5. When target INR was
reached, warfarin was continued as the only antico-
agulation strategy (lifelong in patients receiving
mechanical valves or in those with longstanding per-
sistent atrial fibrillation, limited to the first 3 months
followed by 150 mg/day of acetylsalicylic acid in all
the others).
Endpoints
Due to the fact that the two oxygenators differ
in the technical refinements aimed at reducing the
CPB-related SIRS, the inflammatory response was
set as the primary endpoint of the study. In this
perspective, the perioperative change of high-
sensitivity C-reactive protein (hs-CRP) levels
between the two groups was the primary efficacy end-
point of the study. hs-CRP was measured at three
different timepoints (T0: preoperative, before anes-
thetic induction; T1: at the end of surgery; and T2:
24 h postoperatively).
Secondary endpoint related to the “systemic”
response to CPB was the variation of perioperative
white blood cell (WBC) count, collected at T0 (pre-
operative), T1 (at the end of surgery), T2 (3 h post-
operatively), and T3 (24 h postoperatively).
Other data prospectively collected and considered
as secondary endpoints were the following:
1 PaO2, FiO2, and PaCO2, derived from blood gas
analysis (RapidLab1265AutomaticQC Cartridge,
Siemens Healthcare Italia, Milan, Italy) and
sampled from the arterial line during CPB and
from the cannulated peripheral radial artery
thereafter, at T0: preoperative, T1: at the start of
CPB, T2: immediately before CPB discontinua-
tion, T3: at the end of surgery, T4: 3 h, T5: 24 h
postoperatively.
2 Blood hematocrit (Ht) was collected at T0 (pre-
operative) and at T1–T5 as for PaO2.
3 Red blood cells (RBCs), PLT count, INR, acti-
vated partial thromboplastin time (aPTT),
fibrinogen (FBG), and creatinine (Creat) were
derived from peripheral blood sampling at T0–T3
as for WBC.
4 Serum albumin and total plasma proteins were
assayed at T0 (preoperative),T1 (end of CPB),T2
(end of surgery), and T3 (24 h postoperatively).
5 Pressure drop (in mm Hg) across the two differ-
ent oxygenators was measured at 10 (T1), 20 (T2),
40 (T3), and 60 (T4) min of CPB run.
6 Static and dynamic priming of the two groups.
7 Total intraoperative volume load, defined as the
total amount of volume administered to the
patients (Volume-In), the total amount of volume
lost by the patient (Volume-Out), and the delta
(DVolume) between Volume-In and Volume-Out
during the intraoperative time course.
8 Postoperative bleeding, defined as the total
amount of chest drain loss at 3 (T0), 6 (T1), 12
(T2), and 24 h (T3) postoperatively
9 Transfusions, defined as the volume of allogeneic
red packed cells, plasma, PLTs, and total volume
of transfusions per patient.
10 Clinical outcome was defined by intubation time
(expressed in hours), ICU length of stay and hos-
pital length of stay (expressed in days), hospital
mortality, incidence of perioperative acute myo-
cardial infarction, acute lung injury, acute respira-
tory insufficiency, acute renal insufficiency, acute
renal failure, and type II neurologic complica-
tions, as already reported elsewhere (15). All
these outcome variables were defined according
to the current literature (15).
Statistical analysis
Between–within interactions of three-time
hs-CRP measurement in 40 patients for each study
group gave a power (1-b error probability) of 92.0%
with an a-error probability of 0.05, given a partial
eta-squared of 0.19, and an estimated effect size f
of 0.48.
Pre- and perioperative data were summarized as
mean and standard deviation (SD) or median and
25th–75th percentile if continuous and as counts and
percent if categorical. Continuous variables were
tested for normality with the Shapiro–Wilk test and
compared between the two treatment groups with
the Student’s t-test or the Mann–Whitney U-test
accordingly. Categorical variables were compared
with the Fisher exact test.Ordinal variables were also
compared with Mann–Whitney U-test. Repeated
measures analysis of variance with Bonferroni cor-
rection for multiple measurements was used to
compare serial data. Violations of sphericity were
Greenhouse–Geisser corrected if e < 0.75, or
Huynh–Feldt corrected if e > 0.75. Reported P values
include group-P, assessing level of difference
between groups; time-P, assessing change over time
of measured variables; and group*time-P, assessing
group–time interaction. Comparisons were consid-
ered significant if P < 0.05, unless otherwise dictated
by Bonferroni correction. Statistical analysis was per-
formed by the SPSS program for Windows, version
15.0 (SPSS, Inc., Chicago, IL, USA).
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RESULTS
Baseline characteristics of the two groups were
comparable, as reported in Table 2. Pressure drops
across the two types of oxygenators were also similar,
as shown in Table 3.
Inflammatory response
hs-CRP values at the end of surgery were similar to
those preoperative but showed a significant augmen-
tation at 24 h postoperatively (time-P = 0.0001 for
both groups). This augmentation was significantly
higher in Group-T (group-P = 0.034; group*time-
P = 0.0001, Fig. 1A). However, WBC count signifi-
cantly rose since T1–T3 (time-P = 0.0001 for both
groups) but did not reach the level of statistical sig-
nificance between the two study groups (group-P =
0.673; group*time-P = 0.097; Fig. 1B).
Gas exchange
When the respiratory function was considered,
both oxygenators proved to be highly effective in
achieving adequate oxygenation (PaO2: group-P =
0.067; group*time-P = 0.069), although a slight
decline in this function was detected since T3 in both
groups (time-P = 0.0001 for both; Fig. 2A). Likewise,
comparable PaO2 values were reached with similar
FiO2 administrations (group-P = 0.992; group*time-
P = 0.489; Fig. 2B). Finally, a comparable good CO2-
scavanging effect was demonstrated with both
oxygenators (group-P = 0.323; group*time-P = 0.154;
Fig. 2C).
TABLE 2. Baseline characteristics
Group-T—40 pts Group-S—40 pts P
Age (yr) 76.4 11.1 78.6  4.6 0.257
Male gender 26 (65.0%) 23 (57.5%) 0.647
Diabetes mellitus 20 (50.0%) 13 (32.5%) 0.173
Hypertension 24 (60.0%) 28 (70.0%) 0.482
LVEF 54.8 7.4 52.3  5.6 0.092
Log EuroSCORE 6.9 2.1 7.9  2.4 0.067
Debubbling time
(mins)
4.4  0.5 4.6  0.6 0.090
ACC time (mins) 52.0 7.1 50.1  7.1 0.241
CPB time (mins) 70.3 8.2 73.0  8.8 0.162
ACC, aortic-cross clamping; CPB, cardiopulmonary bypass;
LVEF: left ventricular ejection fraction.
TABLE 3. Pressure drops measured across the two oxygenators, postoperative bleeding, and serum creatinine at different
timepoints (T0 to T3 values of each variable are specified in the text)
Group T0 T1 T2 T3 Time-P Group-P Group*time-P
Pressure drop
(mm Hg)
T 98.6  45.0 101.8  33.6 112.8  45.4 119.1  40.5 0.016 0.980 0.468
S 98.5  38.7 110.3  29.1 110.1  24.9 112.4  20.9 0.020
Bleeding (mL) T 267.1 169.0 360.3  218.7 449.7 231.4 553.0 415.9 0.0001 0.009 0.001
S 166.5 105.8 235.0  140.3 324.2 161.7 430.0 223.5 0.0001
Creatinine (mg/dL) T 1.0 0.2 0.9  0.2 1.0  0.3 1.2  0.3 0.851 0.421 0.290
S 1.0  0.3 1.0  0.3 1.0  0.3 1.2  0.4 0.985
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FIG. 1. Inflammatory response: perioperative leakage of hs-CRP (A) and WBC (B) count in the two groups. CRP, C-reactive protein.
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Hemodilution
Both groups showed a comparable “volume
load” administered by the CPB technicians, in
terms of both static (Group-T = 920.1  90.9 mL vs.
Group-S = 973.7  200.2 mL;P = 0.284) and dynamic
priming (Group-T = 508.5  508.7 mL vs. Group-S =
488.9  571.7 mL; P = 0.911). Similarly, the entire
intraoperative administration of fluids was compa-
rable (Group-T Volume-In = 4609.6  1055.8 mL vs.
Group-S = 4573.4  992.1; P = 0.875) as well as
the intraoperative fluid loss (Group-T Volume-
Out = 1602.0  555.9 mL vs. Group-S = 1630.5 
457.3; P = 0.803) and the intraoperative DVolume
(Group-T = +3007.6  1114.2 mL vs. Group-S =
+2942.9  804.0 mL; P = 0.767).
In spite of the comparable fluid balance, Group-S
showed significantly higher values of serum albumin
(group-P = 0.001, group*time-P = 0.0001; Fig. 3A),
and total proteins (group-P = 0.0001, group*time-
P = 0.0001; Fig. 3B).
Ht values and RBC count—first declin-
ing at T1, rising since T3, and finally reaching
the preoperative values at T5—proved compar-
able between the two groups (Ht: group-P = 0.625,
group*time-P = 0.152; Fig. 3C—RBC count: group-
P = 0.646, group*time-P = 0.703, Fig. 3D), possibly
because of a higher transfusion rate in patients
belonging to Group-T (see later “Hemocoagulative
function” section)
Hemocoagulative function
When the hemocoagulative function was consid-
ered, an overall better profile could be detected in
patients belonging to Group-S (Fig. 4). In detail, PLT
count showed a progressive decline in both groups at
T1 and T2, followed by a slight rise at T3 (time-P =
0.0001 for both).However,Group-S always showed a
higher PLT count compared with Group-T (group-
P = 0.021, group*time-P = 0.0001; Fig. 4A). Similarly,
aPTT significantly prolonged at T1 and T2 in both
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FIG. 2. Gas exchange: perioperative values of PaO2 (A), FiO2 (B), and paCO2 (C) in the two groups.
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groups (time-P = 0.0001) but likewise proved to be
better preserved in Group-S (group-P = 0.0001,
group*time-P = 0.0001; Fig. 4B). FBG levels also
declined at T1 and T2 in both groups (time-P =
0.0001), but higher values were found in Group-S
(group-P = 0.041), also as a function of time
(group*time-P = 0.0001; Fig. 4C). Finally, INR pro-
longed perioperatively in both groups, reaching the
preoperative values only at T3 (time-P = 0.0001);
again, INR prolongation was exacerbated inGroup-T
(group-P = 0.05, group*time-P = 0.05; Fig. 4D).
Patients undergoing Terumo Capiox FX25 showed
a higher postoperative bleeding (group-P = 0.009,
group*time-P = 0.001; Table 3) and a higher transfu-
sion rate (Table 4). However, no patient underwent
re-exploration for bleeding (Table 4).
Clinical outcome
Despite the above-mentioned differences in
various biochemical assays, the two groups did not
differ in all the major clinical outcome variables
(Table 4). Similarly, serum creatinine—regarded as a
marker of perioperative splanchnic perfusion—
proved comparable in the two groups (group-P =
0.421, group*time-P = 0.290; Table 3).
DISCUSSION
Post-CPB SIRS still accounts for a large part of the
mortality and the major morbidity observed after
cardiac surgery (1,2). Recent technological refine-
ments to the CPB machine include the miniaturiza-
tion of the circuits, the integration of different
components (i.e., the arterial filters to minimize
priming and surface exposure to the circulating blood
elements), and the less recent coating of the surfaces
of the CPB machine with heparin (so-called “bioac-
tive” coating) or different types of polymers (so-
called “biopassive” coating), thus mimicking the
endothelial surfaces (1–13).
Indeed, it was since the early 1990s that heparin-
coated circuits were recognized to reduce blood cell
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FIG. 3. Hemodilution: perioperative values of serum albumin (A), total proteins (B), Ht (C), and RBCs (D) in the two groups.
CLINICAL OUTCOME WITH NEW INTEGRATED FILTER OXYGENATORS 7
Artif Organs, Vol. ••, No. ••, 2012
T-Group time-P=.0001
S-Group time-P=.0001
group-P=.05
group*time P=.05
T-Group time-P=.0001
S-Group time-P=.0001
group-P=.041
group*time P=.0001
T-Group time-P=.0001
S-Group time-P=.0001
group-P=.021
group*time P=.0001
T-Group time-P=.0001
S-Group time-P=.0001
group-P=.0001
group*time P=.0001
T1
Time
T2 T3T0
T1
Time
T2 T3T0 T1
Time
T2 T3T0
T1
Time
T2 T3T0
A B
C D
P
LT
s
Fi
b
ri
n
o
g
en
IN
R
200,00
300,00
100,00
400,00
0,00
2,00
1,00
2,00
1,00
1,503,00
5,00
4,00
aP
T
T
1,80
1,60
1,40
1,20
1,00
0,80
0,60
Capiox_or_Synthesis
Terumo Capiox
Sorin Synthesis
Capiox_or_Synthesis
Terumo Capiox
Sorin Synthesis
FIG. 4. Hemocoagulative function: perioperative PLT count (A), aPTT (B), fibrinogen levels (C), and INR (D) in the two groups.
TABLE 4. Transfusions rate/patient and clinical outcome
Group-T—40 pts Group-S—40 pts P
RPCs (mL/pt) 411.7 195.5 66.2  15.0 0.008
PLTs (mL/pt) 15.0 66.2 — 0.156
Plasma (mL/pt) 367.1 217.5 — 0.0001
Total transfusions (mL/pt) 658.9 448.0 66.2  15.0 0.0001
Re-exploration for bleeding — — —
Intubation time (h) 11.6 4.8 10.5 5.2 0.332
ICU-LOS (days) 1.9 0.9 1.9 1.0 0.947
Hospital LOS (days) 6.0 1.4 5.2 1.3 0.112
Mortality — — —
Perioperative AMI — — —
Perioperative ALI — — —
Perioperative acute respiratory insufficiency 1/40 (2.5%) 1/40 (2.5%) 1.0
Perioperative acute renal insufficiency 3/40 (7.5%) 4/40 (10.0%) 1.0
Perioperative acute renal failure 2/40 (5.0%) 1/40 (2.5%) 1.0
Type II neurologic complications 1/40 (2.5%) — 1.0
ALI, acute lung injury;AMI, acute myocardial infarction; ICU, intensive care unit; LOS, length of stay; PLTs, platelets; RPCs, red packed
cells.
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trauma in experimental and clinical scenarios (2). A
more recent paper by Lorusso et al. demonstrated
phosphorylcholine coating to reduce the intraopera-
tive oxygenator inlet pressures, the perioperative
PLT consumption, and the postoperative blood loss,
when compared with uncoated circuits (3). Similarly,
Myers et al. found a better PLT protection after
phosphorylcholine-coated versus uncoated oxygen-
ators (16). X-coating has proven: (i) to reduce the
absorption of plasma proteins (17), (ii) to improve
the entrapment of circulating WBCs with the poten-
tial benefit to attenuate SIRS (18), and (iii) to opti-
mize the hemostasis and to reduce homologous blood
transfusions (19) when compared to uncoated
circuits. Accordingly, the recent 2011 update to the
Society of Thoracic Surgeons/Society of Cardiovas-
cular Anesthesiologists blood conservation clinical
practice guidelines incorporated these evidences and
stated that “the use of biocompatible CPB circuits
may be considered as part of a multimodality
program for blood conservation,” having this state-
ment a Level of Evidence A (20).
Although the majority of the studies on the topic
have proven that these technological improvements
ameliorate the biochemical and clinical outcome
when compared with the traditional CPB machine
(i.e., uncoated circuits, uncoated oxygenators, not
integrated arterial filters, etc.), few studies have com-
pared the different types and settings of these new
technologies (1–13). In the present study on a rela-
tively low risk cohort, we demonstrated that no clini-
cal difference emerged after CPB with either the
Sorin Synthesis oxygenator with phosphorylcholine-
coated circuits or the Terumo Capiox FX25 with
X-coated circuits. Similarly, the two different oxygen-
ators showed similar gas exchange capabilities and
similar results in terms of pressure gradients gener-
ated across the system unit. However, although no
clinical benefit could be demonstrated, patients
belonging to Group-S showed less systemic inflam-
matory reaction (as demonstrated by the lower cir-
culating levels of hs-CRP), together with higher
serum albumins and plasma proteins, in spite of a
comparable hemodilution induced by both the perfu-
sion technicians (i.e., static and dynamic priming) and
the anesthesiologists (i.e., Volume-In, Volume-Out,
and DVolume). Similarly, Group-S showed a better
preserved hemostasis, resulting in reduced postop-
erative bleeding and less need for transfusions.
A possible explanation for these observed out-
comes can be attributed to the different “coating” of
the two CPB settings. To the best of our knowledge,
this is thefirst article aimedat comparing twodifferent
oxygenators, employed with the same manu-
facturer’s circuits and similar surface coatings.
Despite literature lacking direct comparison of the
two coating systems, a recent study by Eisses et al.
demonstrated that pediatric patients undergoingCPB
with X-coated oxygenators, when compared with the
uncoated ones, showed similar thrombin generation
and comparable levels of tissue-plasminogen activa-
tor andplasminogen-activator inhibitor, thus conclud-
ing that no differences existed between the two
systems in the activation of both the coagulation and
the fibrinolytic pathways (21). Similarly, a study by
Izuha et al. in adult patients demonstrated that
changes in overall PLT function associated with the
X-coating were similar to those associated with
heparin coating,although thePLTaggregation thresh-
old index slightly prolonged after X-coating—when
compared with heparin coating—from 60 min to 2 h
of CPB run (22). Another study by Marcoux et al.
investigating five different coated surfaces under-
scored that X-coating CPB correlated with hs-CRP
levels similar to those after the uncoatedCPBand that
X-coating failed to achieve shorter ventilation time or
ICU length of stay compared with the uncoated cir-
cuits (23). The same study showed that X-coating
achieved the worst clinical results—when compared
with the other four different coating technologies—in
terms of transfusion requirements, intubation time,
and ICU length of stay (23). However, literature on
phosphorylcholine coating uniformly proves its supe-
riority when compared with the uncoated circuits. A
study in children by De Somer et al. showed that
phosphorylcholine coating had a favorable effect on
PLTs, given a steady increase of thromboxane-B2 and
beta-thromboglobulin during CPB in the control
group, with an opposite “plateau effect” in the
phosphorylcholine-coated group, a reduced comple-
ment activation after coating, and a resulting reduced
blood loss (24). Another study by the same group in
adult patients confirmed reduced PLT factor-4 and
beta-thromboglobulin levels after phosphorylcholine
coating versus uncoating, resulting in a 30% reduction
in blood loss (25). Myers et al. showed that PLT pro-
tection with phosphorylcholine-coated oxygenators
was significantly better than with uncoated oxygen-
ators, regardless of the employed perfusate (16).
Finally, a recent randomized controlled trial by Pap-
palardoet al.demonstrated that after complex cardiac
procedures, phosphorylcholine-coated oxygenators
reduce the intraoperative thrombin formation and the
associated consumption of PLTs, FBG, and anti-
thrombin (26).
Another possible explanation to our findings can
be related to GME.We know from the literature that
once GME enter the bloodstream, they are coated
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with protein (resulting in larger wall thicknesses) and
are more difficult to break (27). The significance of
protein-coated GME lies in the fact that they have
the ability to create morbidity as solid micro-
emboli (28). Given the direct link between GME and
multiorgan ischemia-reperfusion injury and the
consequent inflammatory response (1), it can be
hypothesized that Group-T patients in our study
experienced a higher rate of postarterial GME.
Indeed, an in vitro study by Myers et al. comparing
five different integral cardiotomy reservoirs found a
significant increase in postarterial GME count when-
ever a vent was employed (as in the aortic surgery of
our patient population) and that GME count was
significantly higher in the Terumo Capiox RX
systems than in the Sorin one (27). Similarly, in
another in vitro study evaluating the air separation
ability of four different extracorporeal circuit
designs, Dickinson et al. proved that the Terumo
system showed an attenuated efficacy in GME
removal (29). Undeniably, the different coating tech-
niques utilized in an oxygenator may result in differ-
ent capability in GME removal from the circulation
(30). Furthermore, despite in vitro demonstration
that the smaller the filter’s pores, the higher the GME
entrapment, researchers have also clearly demon-
strated that the smaller the filter’s pores, the higher
the risk for fragmentation of large bubbles into
microemboli, thus resulting in a higher rate of post-
arterial filter GME count (27).Therefore, due also to
the demonstration in vivo that large amounts of
microbubbles tend to fuse with others after the arte-
rial filter to create larger ones (a term called “coales-
cence”) (27), we cannot definitely prove that the
smaller the filter’s pores, the better the GME removal
(and consequently the better the outcome).
Furthermore, despite the fact that GME can be
generated at any time of CPB conductance, we can
assume that the two groups at least start with a
similar “microembolic” load, given the similar preop-
erative debubbling time. Certainly, we can only
speculate at the moment on this issue, given the fact
that a major limitation in the interpretation of our
results is related to the lack of postarterial filter
GME count, which is indeed the objective of an
ongoing study at our institution.
Finally, the efficacy of hs-CRP, as a marker of the
systemic inflammatory response to CPB after cardiac
surgery, and its prognostic role for cardiovascular
mortality and morbidity, have been well documented
(31).Asmentioned above,both the better biocompat-
ibility of the phosphorylcholine coating and the
potential better GME removal—with a lower multio-
rgan ischemia/reperfusion injury—may help to ex-
plain the lower inflammation found in Group-S
(4,14,15,28). Furthermore, the lower hs-CRP leakage
in the Sorin group may help to explain its better
hemocoagulative profile,given thedirect linkbetween
inflammatory and coagulative/fibrinolytic cascades
(32).
From a scientific point of view, it has to be consid-
ered that the involvement of two or more perfusion-
ists might have impacted the analyzed outcome
variables. However, the strict adherence to the stan-
dardized CPB protocol was considered mandatory
for the enrollment of any patient in this study.
Furthermore, an “ideal” comparison would have
involved another two groups of treatment, with the
same circuits but opposite surface coatings; however,
the availability of the only two reported types of
oxygenators,with the only two corresponding coating
materials, avoided this ideal comparison.
CONCLUSION
The result of our study demonstrated that despite
comparable gas exchange,hemodilution,and pressure
gradients, a significant attenuation of the inflamma-
tory response to CPB was evidenced in patients
belonging to Group-S, possibly related to a higher
biocompatibility of the Sorin system in terms of
coating, and to a lower degree of systemic GME
related to the specific characteristics of the investi-
gated device. The direct relationship among systemic
inflammation,coagulation,andfibrinolysis (32) antici-
pates also the lower hemocoagulative dysfunction
(with consequent lower perioperative bleeding and
need for transfusions) experienced by Group-S.
However, the reported biochemical differences did
not translate into a better clinical outcome in any of
the two groups. Further studies enrolling patients at a
higher risk profile might help to find out the potential
clinical benefits of these new generation integrated
oxygenators.
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